Compare Deutsche Bank AG (DB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Neurocrine Biosciences Inc — how do they compare? Deutsche Bank AG trades at $33.74 (market cap $62.42B), while Neurocrine Biosciences Inc trades at $142.19 (market cap $14.36B). The key difference: Deutsche Bank AG is far larger — about 4.3× Neurocrine Biosciences Inc's market cap, and Deutsche Bank AG pays a 3.46% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DB | NBIX | |
|---|---|---|
Market Cap | $62.42B | $14.36B |
Volume | 2,918,760 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $41.56 | $185.50 |
52-Week Low | $28.37 | $123.10 |
Typical Hold Time | 80 Days | 23 Days |
Enterprise Value | $77.06B | $14.37B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.58, showing minimal daily movement (+0.09%). The stock presents mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 9.09 and P/B of 0.71. Recent earnings show volatility with a Q2 2026 miss but strong Q1 2026 beat. The company demonstrates improved financial health with 2025 net cash flow of $7.61B and rising revenue trends from $30.0B in 2024 to $32.1B in 2025.
DB offers value investment potential with below-market valuations and positive cash flow generation, though technical weakness and mixed analyst sentiment (21% buy, 58% hold) suggest cautious optimism. Key risks include investment banking revenue volatility and significant workforce retirement challenges. The path to 2028 targets depends on wealth management growth and cost control execution.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
